RUNX1 and acute myeloid leukemia: Over the past decades, several gene mutations such as internal tandem duplication (ITD) of the FLT3 gene, mutations in the NPM1 gene, partial tandem duplication of the MLL gene, mutations in the CEBPA gene, and changes in gene expression, such as overexpression of BAALC, ERG, EVI1, MN1 and CDKN1B, have been discovered to strongly affect clinical outcome of CN-AML patients [3,4].